Intravenous dexamethasone for idiopathic sudden sensorineural hearing loss:clinical evaluation / 中国基层医药

ABSTRACT

Objective To investigate clinic efficacy of intravenous dexamethasone for idiopathic sudden sensorineural hearing loss.Methods Subjects received a 10-day dexamethasone(10mg/d) course.4-frequency(500,1000,2000,4000Hz) pure-tone averages(PTA) calculated using air conduction thresholds pre-treatment and post-treatment were compared.A clinically significant chanage in PTA was considered to be greater than 10dB HL.Results PTA of pre-treatment and post-treatment were(66.32?23.66)dB HL and(45.61?25.24)dB HL,respectively,in 40 patients with idiopathic sudden sensorineural hearing loss.There was significant improvement in PTA,P=0.000756.90% of patients showed improvement in hearing.Promising results were found with intravenous dexamethasone in cases with shorter time to treatment or/and without vertigo.Conclusion Intravenous dexamethasone can be beneficial in treating patient with idiopathic sudden sensorineural hearing loss.Prognostic indicators include time to treatment and vertigo.